Gonorrhea Therapeutics Market to Reflect Impressive Growth Rate During 2017-2025
The World Health Organization (WHO) estimated that the global incidence of gonorrhea increased from 87.7 million in 2005 to 106.1 million in 2008. An article published by Newman et al (2015) estimated the global prevalence of gonorrhea at 0.8% among women aged 15 years to 49 years and 0.6% among men in the same age group in 2012. Rise in new cases of gonorrhea, public awareness about the disease, high rate of diagnosis, high risk of complications, novel therapeutic options, and government regulations about antibiotic uses are the major drivers of the global gonorrhea therapeutics market. However, antibiotic-resistant gonorrhea is a growing concern among physicians.
Report Overview and TOC @ https://www.transparencymarketresearch.com/gonorrhea-therapeutics-market.html
The Centers for Disease Control and Prevention recommends two types of therapy for gonorrhea: mono therapy (single dose of 2g oral azithromycin) and dual therapy (single dose of 250 mg of ceftriaxone and 1g of azithromycin). Babies born to mothers with gonorrhea receive a medication in their eyes immediately after birth. Based on therapy, the global gonorrhea therapeutics market can be segmented into mono therapy and dual therapy. In terms of route of administration, the market can be categorized into enteral, parenteral, and topical.
Based on distribution channel, the global gonorrhea therapeutics market can be classified into hospital pharmacies, retail pharmacies, and online sales. The numbers of retail pharmacies are increasing with the growing number of registered pharmacists who can dispense antibacterial drugs for gonorrhea treatment. On the other hand, the hospital pharmacies witness small growth in revenue due to the consolidations (joint venture, merger and acquisitions) among hospitals.
Request for Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36140
The global gonorrhea therapeutics market can be segmented into five major regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. According to the CDC, around 468,514 cases of gonorrhea were reported in the U.S. in 2016, with a rate of 145.8 cases per 100,000. More significantly, the disease is not prevalent in any specific age group. Ontario, Canada reported 30% increase in gonorrhea affected patients between 2013 and 2015. The European Centre for Disease Prevention and Control (ECDC) indicated that 66,413 cases of gonorrhea were registered in Europe in 2016. The same organization also revealed that the U.K., Ireland, and Denmark reported higher number of confirmed cases, although Eastern Europe exhibited higher prevalence of gonorrhea due to low public awareness. According to the International Journal of Infectious Disease, in 2014, the annual incidence of gonorrhea was 4.0 to 27.3 per 1,000 in Asia. Latin America represented a higher rate of gonorrhea cases at 27.9 per 1,000, while Africa exhibited highest rate of gonorrhea (63.3 per 1,000 population). Lack of diagnosis and treatment, inadequate public awareness, and insufficient health care infrastructure are the key factors for high rate of gonorrhea in Sub-Saharan Africa. Conservative culture and improved health care facilities in countries in the Middle East such as Saudi Arabia and Israel lower the prevalence of gonorrhea affected victims.
Pre Book Full Report @ https://www.transparencymarketresearch.com/gonorrhea-therapeutics-market.html?secure=NTIxNS41&type=PB
Key players in the global gonorrhea therapeutics market are Bharat Pharmaceuticals, GlaxoSmithKline, Merck Millipore, Pfizer, Entasis Therapeutics, Inc., and Melinta Therapeutics among others. Zoliflodacin is a novel antibiotic drug for the treatment of uncomplicated gonorrhea which will be launched through a collaborative efforts of Entasis Therapeutics and the Global Antibiotic Research and Development Partnership. Melinta Therapeutics delivered a prospect of another novel antibiotic agent RX-P2177 to treat gonorrhea in July, 2017.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-345
This release was published on openPR.
Permanent link to this press release:
You can edit or delete your press release Gonorrhea Therapeutics Market to Reflect Impressive Growth Rate During 2017-2025 here
News-ID: 866522 • Views: 123
More Releases from Transparency Market Research
Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15
More Releases for Therapeutics
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy. Download the sample report @ https://www.pharmaproff.com/request-sample/1077 Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy. Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis The
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other